Clinical and Laboratory Features of Patients Enrolled in the ALL-AIEOP91 and ALL-BFM90 Protocols Analyzed for the Prognostic Impact of the t(12; 21) Translocation
| . | TEL/AML1 Positive . | TEL/AML1 Negative . | ||
|---|---|---|---|---|
| . | n = 99 (28.9%) . | n = 243 (71.1%) . | ||
| . | . | . | . | . |
| Sex | ||||
| Male | 53 | 54% | 129 | 53% |
| Female | 46 | 46% | 114 | 47% |
| Age (yr) | ||||
| <1 | 0 | 7 | 3% | |
| 1-5 | 74 | 75% | 159 | 65% |
| 6-9 | 19 | 19% | 34 | 14% |
| 10-14 | 6 | 6% | 43 | 18% |
| WBC | ||||
| <20,000 | 65 | 66% | 159 | 66% |
| 20-100,000 | 20 | 20% | 56 | 23% |
| ≥100,000 | 14 | 14% | 28 | 12% |
| Immunophenotype | ||||
| Common | 84 | 85% | 183 | 75% |
| Pre-B | 15 | 15% | 49 | 20% |
| Pre-pre-B | 0 | 6 | 2% | |
| Not known | 0 | 5 | 3% | |
| Protocol | ||||
| Standard risk | 27 | 27% | 61 | 25% |
| Intermediate risk | 72 | 73% | 182 | 75% |
| . | TEL/AML1 Positive . | TEL/AML1 Negative . | ||
|---|---|---|---|---|
| . | n = 99 (28.9%) . | n = 243 (71.1%) . | ||
| . | . | . | . | . |
| Sex | ||||
| Male | 53 | 54% | 129 | 53% |
| Female | 46 | 46% | 114 | 47% |
| Age (yr) | ||||
| <1 | 0 | 7 | 3% | |
| 1-5 | 74 | 75% | 159 | 65% |
| 6-9 | 19 | 19% | 34 | 14% |
| 10-14 | 6 | 6% | 43 | 18% |
| WBC | ||||
| <20,000 | 65 | 66% | 159 | 66% |
| 20-100,000 | 20 | 20% | 56 | 23% |
| ≥100,000 | 14 | 14% | 28 | 12% |
| Immunophenotype | ||||
| Common | 84 | 85% | 183 | 75% |
| Pre-B | 15 | 15% | 49 | 20% |
| Pre-pre-B | 0 | 6 | 2% | |
| Not known | 0 | 5 | 3% | |
| Protocol | ||||
| Standard risk | 27 | 27% | 61 | 25% |
| Intermediate risk | 72 | 73% | 182 | 75% |